Longitudinal Circulating Tumor DNA–Guided Resistance Analysis During Second-Line Osimertinib Treatment
In 33% of patients treated with second- or third-line osimertinib, RMs in plasma preceded PD by a median of 14 weeks, suggesting an opportunity for early treatment adjustment, potentially extending tyrosine kinase inhibitor treatment duration.
Authors
- M. Jebbink (ORCID: https://orcid.org/0000-0003-0290-804X)
- Tijmen J.W.T. van der Wel (ORCID: https://orcid.org/0000-0002-9128-1930)
- Egbert F. Smit (ORCID: https://orcid.org/0000-0002-7329-6995)
- Vincent van der Noort (ORCID: https://orcid.org/0000-0002-4910-4535)
- Linda J.W. Bosch (ORCID: https://orcid.org/0000-0001-6323-9316)
- Ferry Lalezari (ORCID: https://orcid.org/0000-0002-1777-3259)
- Kim Monkhorst (ORCID: https://orcid.org/0000-0002-8690-3811)
- Adrianus J. de Langen (ORCID: https://orcid.org/0000-0001-7343-633X)
- P. Baas
- Elisabeth A. Kastelijn (ORCID: https://orcid.org/0000-0001-8954-2452)
- Anne S. R. van Lindert (ORCID: https://orcid.org/0000-0002-4072-2441)
- Marrit Vermeulen
- Mirjam C. Boelens
- Daan van den Broek (ORCID: https://orcid.org/0000-0002-2765-7139)
- Jacobus A. Burgers
- G. Ruiter
- Ernst E. van der Wall
Institutions
- Leiden University Medical Center (NL)
- The Netherlands Cancer Institute (NL)
- University Medical Center Utrecht (NL)
- Medisch Centrum Haaglanden (NL)
- St. Antonius Ziekenhuis (NL)
- Oncode Institute (NL)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100853
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Roche Nederland
- Ministerie van Volksgezondheid, Welzijn en Sport
- KWF Kankerbestrijding